Aldeyra Therapeutics enters the second half of 2026 as a pre-revenue ophthalmology and immunology biotech whose defining asset, the dry-eye therapy reproxalap, has now been rejected by the U.S. Food and Drug Administration three separate times. The most damaging data point arrived on March 17, 2026, when the agency issued its third Complete Response Letter, a formal refusal to approve the new drug application, stating plainly that the totality of evidence from the completed clinical trials did not support the drug's effectiveness for the signs and symptoms of dry eye disease. For the quarter ended June 30, 2026, the company reported a net loss of $5.5 million, down from a $9.8 million loss a year earlier, on research and development expense of $3.5 million and general and administrative expense of $2.4 million, with $45.1 million of cash on the balance sheet and a market capitalization near $94 million at the mid-August 2026 price of roughly $1.56 per share.
The equity now trades at the intersection of two opposing forces. On one side stands a badly damaged but still liquid balance sheet: roughly $45 million of cash, zero debt following the April 2026 payoff of the Hercules Capital loan, and a disclosed runway that management believes extends into the second half of 2028. On the other side stands a regulatory pathway that is genuinely uncertain, because the FDA has now said three times that the dry-eye data do not convince it, and the company's flagship commercial partner, AbbVie, has not yet exercised the option it holds on reproxalap as of August 6, 2026. In our view the market is pricing Aldeyra mostly as a cash-and-optionality story, where the value of the reproxalap franchise itself has largely been written down after the third rejection, and where the stock's next meaningful move depends on whether management can persuade the FDA to accept yet another resubmission.
The single load-bearing risk is that the FDA, through the Type D meeting expected by the end of the third quarter of 2026, requires additional clinical trials before the agency reconsiders a reproxalap resubmission. A costly new trial requirement would both drain the disclosed runway and further delay the AbbVie option, whose exercise window opens ten business days after any approval. The falsifiable clock for this thesis is the outcome and tone of that Type D meeting, plus any guidance the company gives about a fourth resubmission; the next quarterly print and the resolution of the securities class action filed in March 2026 are the secondary data points that test whether the current cash-value-plus-option framing holds up.